Economic analysis of carboplatin versus cisplatin in lung and ovarian cancer
Related Articles
- The economic consequences of breast cancer adjuvant hormonal treatments. Pezzin, Liliana E.; O'Niel, Mallory B.; Nattinger, Ann B. // JGIM: Journal of General Internal Medicine;Nov2009 Supplement 2, Vol. 24, p446
Rationale: Adjuvant hormone therapy (HT) based on tamoxifen (TX) or aromatase inhibitors (AIs) has become the standard of care for treating hormone receptor -positive (HR+) breast cancer (BC) over the past 20 years. Based on clinical trial results, AI use is recommended by the... - Cisplatin/carboplatin. // Reactions Weekly;7/22/2006, Issue 1111, p10
The article presents a case study of a 47-year-old woman who was diagnosed with cancer metastases while being treated with cisplatin and carboplatin for ovarian cancer.
- Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors. Salazar, Ramón; Calles, Antonio; Gil, Marta; Durán, Ignacio; García, Margarita; Hidalgo, Manuel; Coronado, Cinthya; Alfaro, Vicente; Siguero, Mariano; Fernández-Teruel, Carlos; Prados, Raquel; Calvo, Emiliano // Investigational New Drugs;Aug2014, Vol. 32 Issue 4, p644
This phase I trial determined the recommended dose for phase II trials (RD) of carboplatin 1-h intravenous (i.v.) infusion followed by PM00104 1-h i.v. infusion on Day 1 every 3 weeks (q3wk) in adult patients with advanced solid tumors. A toxicity-guided, dose-escalation design was used....
- Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies-results of a phase I dose-escalation study. Blais, Normand; Camidge, D.; Jonker, Derek; Soulières, Denis; Laurie, Scott; Diab, Sami; Ruiz-Garcia, Ana; Thall, Aron; Zhang, Ke; Chao, Richard; Chow, Laura // Investigational New Drugs;Dec2013, Vol. 31 Issue 6, p1487
Objectives The maximum tolerated dose (MTD) and overall safety of sunitinib plus pemetrexed and carboplatin was determined in patients with advanced solid malignancies. Methods In this phase I dose-escalation study, patients received oral sunitinib on a continuous daily dosing (CDD) schedule...
- Experimental exposure of male volunteers to N-methyl-2-pyrrolidone (NMP): acute effects and pharmacokinetics of NMP in plasma and urine. Akesson, B.; Paulsson, K // Occupational & Environmental Medicine;Apr1997, Vol. 54 Issue 4, p236
Objectives: To study the acute effects of exposure to the increasingly used solvent, N-methyl-2-pyrrolidone (NMP) in male volunteers. Further, to determine the NMP concentration in plasma and urine during and after the exposure.Methods: Six male volunteers were exposed... - Influenza immunization in a managed care organization. Baker, Ann M.; McCarthy, Bruce; Gurley, Virginia F.; Yood, Marianne Ulcickas; Baker, Ann; Baker, A M; McCarthy, B; Gurley, V F; Yood, M U // JGIM: Journal of General Internal Medicine;Jul1988, Vol. 13 Issue 7, p469
Objective: To compare the effects of different types of computer-generated, mailed reminders on the rate of influenza immunization and to analyze the relative cost-effectiveness of the reminders.Design: Randomized controlled trial.Setting: Multispecialty... - Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICOENGOT-GCIG intergroup study (HECTOR) Sehouli, J.; Chekerov, R.; Reinthaller, A.; Richter, R.; Gonzalez-Martin, A.; Harter, P.; Woopen, H.; Petru, E.; Hanker, L. C.; Keil, E.; Wimberger, P.; Klare, P.; Kurzeder, C.; Hilpert, F.; Belau, A. K.; Zeimet, A.; Bover-Barcelo, I.; Canzler, U.; Mahner, S.; Meier, W. // Annals of Oncology;Dec2016, Vol. 27 Issue 12, p2236
Background: Randomized, phase III trial to evaluate safety and efficacy of topotecan and carboplatin (TC) compared with standard platinum-based combinations in platinum-sensitive recurrent ovarian cancer (ROC). Patients and methods: Patients were randomly assigned in a 1:1 ratio to the...
- Weekly carboplatin, paclitaxel improved quality of life in advanced ovarian cancer. // Hem/Onc Today;7/25/2014, Vol. 15 Issue 14, p11
The article discusses a phase three clinical study which concluded that women patients with advanced ovarian cancer receiving weekly first-line carboplatin and paclitaxel demonstrated improved quality of life as compared to women receiving the regimen once every three weeks.
- Neurocognitive functioning in schizophrenia: a trial of risperidone versus haloperidol. Addington, Jean; Addington, Donald; Addington, J; Addington, D // Canadian Journal of Psychiatry;Nov1997, Vol. 42 Issue 9, p983
A letter to the editor is presented regarding neurocognitive functioning in schizophrenia: A trial of risperidone versus haloperidol.